ABN Amro Investment Solutions Acquires 13,431 Shares of Amgen Inc. $AMGN

ABN Amro Investment Solutions grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 23.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 71,002 shares of the medical research company’s stock after purchasing an additional 13,431 shares during the period. ABN Amro Investment Solutions’ holdings in Amgen were worth $23,240,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. Capital International Investors increased its holdings in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares in the last quarter. Capital World Investors increased its holdings in shares of Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after buying an additional 1,935,876 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of Amgen by 2.7% during the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock worth $1,335,168,000 after buying an additional 122,631 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Amgen by 6.6% during the third quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock worth $1,260,668,000 after buying an additional 277,031 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on AMGN. Truist Financial upped their price target on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Oppenheimer set a $400.00 price target on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday, February 5th. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Finally, Rothschild & Co Redburn upped their price target on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $355.19.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.85% of the stock is owned by insiders.

Amgen Stock Performance

NASDAQ AMGN opened at $331.57 on Thursday. The company has a market capitalization of $178.94 billion, a price-to-earnings ratio of 23.07, a PEG ratio of 3.32 and a beta of 0.44. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The stock has a fifty day simple moving average of $346.62 and a 200 day simple moving average of $344.14. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.